2010-12-01 · Both CLSI and EUCAST have established clinical breakpoints (CBP) for fluconazole and Candida by taking into account the MIC distributions, pharmacokinetic (PK) and pharmacodynamic (PD) parameters, and clinical outcomes as they relate to MIC values (Cuesta et al., 2009, Pfaller et al., 2006, Rodriguez-Tudela et al., 2007b).

1843